Ester Neurosciences Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $15M

Ester Neurosciences General Information

Description

Developer of therapeutic products for the treatment of neurological disorders. The company provides novel therapeutic products for the treatment of neurological disorders such as myasthenia gravis, alzheimer disease, multiple sclerosis and acute stress reactions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Ackerstein Towers, Building B
  • 10th Floor, 11 Hamanofim Street
  • Herzliya 46725
  • Israel
+972
Primary Industry
Other Devices and Supplies
Vertical(s)
Corporate Office
  • Ackerstein Towers, Building B
  • 10th Floor, 11 Hamanofim Street
  • Herzliya 46725
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ester Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Dec-2007 $15M Completed Clinical Trials - Phase 2
1. Early Stage VC Completed
To view Ester Neurosciences’s complete valuation and funding history, request access »

Ester Neurosciences Patents

Ester Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2007237059-A1 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases Active 10-Apr-2006
AU-2007237059-B2 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases Inactive 10-Apr-2006
CA-2648980-A1 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases Inactive 10-Apr-2006
EP-2007399-A2 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases Inactive 10-Apr-2006
US-20090275634-A1 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases Inactive 10-Apr-2006 C12N15/1137
To view Ester Neurosciences’s complete patent history, request access »

Ester Neurosciences Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Medica Venture Partners Venture Capital Minority
To view Ester Neurosciences’s complete investors history, request access »

Ester Neurosciences FAQs

  • When was Ester Neurosciences founded?

    Ester Neurosciences was founded in 1997.

  • Where is Ester Neurosciences headquartered?

    Ester Neurosciences is headquartered in Herzliya, Israel.

  • What industry is Ester Neurosciences in?

    Ester Neurosciences’s primary industry is Other Devices and Supplies.

  • Is Ester Neurosciences a private or public company?

    Ester Neurosciences is a Private company.

  • What is the current valuation of Ester Neurosciences?

    The current valuation of Ester Neurosciences is .

  • What is Ester Neurosciences’s current revenue?

    The current revenue for Ester Neurosciences is .

  • Who are Ester Neurosciences’s investors?

    Medica Venture Partners has invested in Ester Neurosciences.

  • When was Ester Neurosciences acquired?

    Ester Neurosciences was acquired on 01-Dec-2007.

  • Who acquired Ester Neurosciences?

    Ester Neurosciences was acquired by Amarin Corporation.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process